Montelukast Normon

Montelukast, the active ingredient in Montelukast Normon, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is indicated for maintenance therapy of asthma, relief of allergic rhinitis symptoms, and prevention of exercise‑induced bronchoconstriction in appropriate patient groups.

GNH USA supplies Montelukast Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control chronic airway inflammation and allergic symptoms.

- Asthma (maintenance therapy): reduces frequency of symptoms and exacerbations. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Diarrhea - Fatigue

Serious or Rare Side Effects: - Allergic reactions such as angioedema, rash or urticaria - Neuropsychiatric events including depression or suicidal thoughts - Elevated liver enzymes - Eosinophilic granulomatosis with polyangiitis - Severe skin reactions such as Stevens‑Johnson syndrome

Before initiating therapy, consider the following safety measures.

- Liver function monitoring: obtain baseline hepatic enzymes. - Neuropsychiatric assessment: watch for mood changes or suicidal ideation. - Hepatic impairment: use with caution in severe liver disease. - Drug metabolism: review concomitant medications that induce or inhibit CYP enzymes. - Renal function: adjust if significant renal impairment is present. - Store at room temperature: keep in the original container, protect from moisture and heat.

Montelukast may interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce montelukast exposure. - Phenobarbital: can lower therapeutic effectiveness.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., SSRIs): may increase risk of neuropsychiatric side effects. - Warfarin: potential alteration of INR values. - Short‑acting β2‑agonists: additive bronchodilatory effect may require dose adjustment.